NICE
NICE rules Shire’s Onivyde not cost effective
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire
Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
NICE approves Roche’s Perjeta for breast cancer
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer
NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
NICE turns down Amgen’s multiple myeloma drug
November 9, 2016Research and Development, Sales and Marketing Amgen, Kyprolis, NICE
Amgen has seen its drug Kyprolis (carfilzomib) rejected by NICE for its routine use in the treatment of multiple myeloma …
AstraZeneca’s post-heart attack drug gets NICE recommendation
November 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack
AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …
Celgene’s Otezla approved by NICE for chronic plaque psoriasis
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, NICE, apremilast, otezla
NICE has given its approval to another indication for Celgene’s Otezla (apremilast), meaning NHS patients now have access to the …
NICE plans new “fast-track” appraisal option
October 14, 2016Medical Communications, Sales and Marketing NHS, NICE
The National Institute for Health and Care Excellence (NICE) has proposed the introduction of a fast-track process which could make …
NICE knocks back Janssen rare disease drug
October 13, 2016Medical Communications Janssen, NICE, imbruvica
NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …
NICE backs Celgene’s Otezla for psoriatic arthritis
October 12, 2016Research and Development, Sales and Marketing Celgene, NICE, otezla
The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …
NICE recommends Forxiga in Triple Therapy for Diabetes
October 7, 2016Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes
The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …
Merck’s Keytruda suffers rejection at hands of NICE
October 5, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda
NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
NICE and the CDF: Are they still up to scratch?
October 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE
Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …
NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic
September 30, 2016Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo
The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …
NICE approves Bayer’s Eylea for NHS use
September 28, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE
Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …
Provisional NICE recommendation for Gilead’s Hepatitis C treatment
September 28, 2016Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C
NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …
NICE rejects expanded treatment indication for Roche’s Esbriet
September 19, 2016Sales and Marketing Esbriet, NICE, Roche, rejection
NICE has published a final appraisal rejecting the expanded use of Roche’s Esbriet (pirfenidone) for the treatment of early idiopathic …
Latest content
FibroFind appoints Lee Borthwick as CEO
